From: In vivo optical quality of posterior-chamber phakic implantable collamer lenses with a central port
Authors | Year | Eyes (patients) | Follow-up | SE (D) | Device |
---|---|---|---|---|---|
Shimizu et al. [8] | 2012 | 29 (29) | 3 mo | −7.52 ± 2.02 | KR-9000(Topcon, Tokyo, Japan) |
Hosny and Shalaby [9] | 2013 | 20 (NR) | 1.5 mo | −12.9 ± 2.38 | ViSX Wavescan(Johnson & Johnson Vision, Jacksonville, USA) |
Kamiya et al. [10] | 2014 | 28 (28) | 3 mo | −7.17 ± 1.98 | OQAS (Keeler, Malvern, USA) |
Huseynova et al. [11] | 2014 | 44 (44) | 3 mo | −10.05 ± 2.72 | KR-1 W (Topcon, Tokyo, Japan) |
Tian et al. [12] | 2017 | 18 (18) | 1 mo | −11.44 ± 5.18 | iTrace (Tracey Technologies, Houston, USA) |
Park et al. [13]a | 2017 | 46 (28) | 3 mo | −8.58 ± 2.08 | KR-1 W (Topcon, Tokyo, Japan)OQAS (Keeler, Malvern, USA) |
Miao et al. [14] | 2018 | 67 (38) | 3 mo | −12.44 ± 3.15 | OQAS (Keeler, Malvern, USA) |
Liu et al. [15] | 2018 | 40 (22) | 3 mo | −6.12 ± 2.19 | ViSX Wavescan(Johnson & Johnson Vision, Jacksonville, USA)OQAS (Keeler, Malvern, USA) |
Qin et al. [16] | 2019 | 30 (15) | 3 mo | −13.87 ± 2.16 | iTrace (Tracey Technologies, Houston, USA) |
Wan et al. [17]b | 2020 | 27 (27)29 (29)54 (54)27 (27) | 6 mo | −5.33 ± 0.83−8.01 ± 0.82−10.67 ± 0.94− 14.01 ± 1.47 | WASCA (Carl Zeiss Meditec AG, Jena, Germany) |
Niu et al. [18] | 2020 | 39 (20) | 12 mo | −7.54 ± 1.07 | OQAS (Keeler, Malvern, USA) |
Wei et al. [19] | 2020 | 94 (57) | 6 mo | −8.07 ± 1.03 | WASCA (Carl Zeiss Meditec AG, Jena, Germany) |
Wei et al. [20]c | 2020 | 42 (21)46 (23) | 6 mo | −8.26 ± 1.43− 8.30 ± 1.43 | WASCA (Carl Zeiss Meditec AG, Jena, Germany) |
Zhang et al. [21] | 2020 | 16 (8) | 6 mo | −4.26 ± 1.55 | OQAS (Keeler, Malvern, USA) |
Baptista et al. [22] | 2020 | 30 (15) | 38.5 mo | −8.25 ± 2.6 | OQAS (Keeler, Malvern, USA) |
Chen et al. [23] | 2021 | 59 (59) | 1 week | −15.16 ± 4.77 | OQAS (Keeler, Malvern, USA) |
Aruma et al. [24] | 2021 | 32 (20) | 12 mo | −5.21 ± 0.73 | WASCA (Carl Zeiss Meditec AG, Jena, Germany)OQAS (Keeler, Malvern, USA) |